Biohaven Receives 'Moderate Buy' Rating from Analysts

Eighteen research firms cover the biopharmaceutical company's stock

Apr. 16, 2026 at 6:34am

Got story updates? Submit your updates here. ›

Shares of Biohaven Ltd. (NYSE:BHVN) have been assigned an average 'Moderate Buy' rating from eighteen research firms currently covering the stock, according to a MarketBeat report. The analysts' average 12-month price target for the stock is $22.53.

Why it matters

Biohaven is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and neurovascular diseases. The 'Moderate Buy' rating from analysts suggests they see potential upside in the company's stock despite some near-term challenges.

The details

The analyst ratings for Biohaven break down as follows: one 'sell' recommendation, five 'hold' recommendations, nine 'buy' recommendations, and three 'strong buy' recommendations. The average 12-month price target of $22.53 represents potential upside of over 100% from the stock's current trading price around $10.35.

  • Biohaven's stock has traded between $7.48 and $24.06 over the past 52 weeks.
  • The company reported Q4 2025 earnings on March 2, 2026.

The players

Biohaven Ltd.

A clinical-stage biopharmaceutical company focused on developing therapies for neurological and neurovascular diseases.

MarketBeat

A financial media company that tracks Wall Street analyst ratings and price targets.

Got photos? Submit your photos here. ›

What’s next

Biohaven is expected to provide a business update and report Q1 2026 financial results in the coming weeks.

The takeaway

The 'Moderate Buy' rating from analysts suggests cautious optimism around Biohaven's prospects, with the potential for significant upside if the company can execute on its pipeline of neurological disease treatments.